A PHASE 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DCR-PHXC SOLUTION FOR INJECTION (SUBCUTANEOUS USE) IN PATIENTS WITH PRIMARY HYPEROXALURIA (PLACEBO CONTROLLED)

Registry ID

DCR-PHXC-201

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

DICERNA PHARMACEUTICALS INC

Start date

2019-11-25

Completion date

2021-06-21

Last update

2019-01-21

Conditions

• HYPEROXALURIA

Related clinical trials

• PHASE 1-2A SAFETY, TOLERABILITY, AND PHARMACODYNAMICS CONTROLLED STUDY OF NOV-001 IN HEALTHY VOLUNTEERS AND PATIENTS WITH ENTERIC HYPEROXALURIA
• EVALUATE THE SAFETY AND EFFICACY OF RELOXALIASE (OXALATE DECARBOXYLASE) IN PATIENTS WITH ENTERIC HYPEROXALURIA: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (URIROX-2)
• AN OPEN-LABEL ROLL-OVER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DCR-PHXC SOLUTION FOR INJECTION (SUBCUTANEOUS USE) IN PATIENTS WITH PRIMARY HYPEROXALURIA

View on source registry